Cargando…

Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients

BACKGROUND: Invasive fungal infection (IFI) is one of the leading causes of early death after renal transplantation. Voriconazole (VRC) is the first-line drug of IFI. Because of the large inter- and intraindividual variability in VRC plasma concentrations and the narrow therapeutic window for treati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zi-Wei, Peng, Feng-Hua, Yan, Miao, Liang, Wu, Liu, Xiao-Lei, Wu, Yan-Qin, Lin, Xiao-Bin, Tan, Sheng-Lan, Wang, Feng, Xu, Ping, Fang, Ping-Fei, Liu, Yi-Ping, Xiang, Da-Xiong, Zhang, Bi-Kui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Therapeutic Drug Monitoring 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538305/ https://www.ncbi.nlm.nih.gov/pubmed/28604474 http://dx.doi.org/10.1097/FTD.0000000000000425

Ejemplares similares

Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients
por: Zhao, Yi‐Chang, et al.
Publicado: (2020)

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
por: Shi, Hui-Yan, et al.
Publicado: (2010)

The Effect of Voriconazole on Tacrolimus in Kidney Transplantation Recipients: A Real-World Study
por: Zhao, Yi-Chang, et al.
Publicado: (2022)

Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients
por: Hu, Lin, et al.
Publicado: (2023)

Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children
por: Zhao, Yi-Chang, et al.
Publicado: (2021)

Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in children
por: Chen, Xiaomin, et al.
Publicado: (2022)

CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
por: Li, Yi, et al.
Publicado: (2015)

Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization
por: Ma, Kui-fen, et al.
Publicado: (2020)

1129. Targeted Voriconazole Prophylaxis in Heart Transplantation Recipients
por: Lin, Michael, et al.
Publicado: (2018)

Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
por: Zhong, Xuefeng, et al.
Publicado: (2018)

Application of Population Pharmacokinetic Analysis to Characterize CYP2C19 Mediated Metabolic Mechanism of Voriconazole and Support Dose Optimization
por: Li, SiChan, et al.
Publicado: (2022)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

Voriconazole-induced Myositis in a Double Lung Transplant Recipient
por: Soliman, Mohanad, et al.
Publicado: (2019)

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
por: Chung, Hyewon, et al.
Publicado: (2015)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique
por: Wang, Hui-jun, et al.
Publicado: (2021)

Predicting the Outcome of Voriconazole Individualized Medication Using Integrated Pharmacokinetic/Pharmacodynamic Model
por: Yang, Ping, et al.
Publicado: (2021)

Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections
por: Miao, Qiang, et al.
Publicado: (2019)

Fusarium Infection in a Kidney Transplant Recipient Successfully Treated with Voriconazole
por: Alkhunaizi, Ahmed M., et al.
Publicado: (2018)

Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats
por: Shen, Jiquan, et al.
Publicado: (2020)

2566. Effect of CYP2C19 on Voriconazole Pharmacokinetics in Children with Malignancy or Inborn Errors in Immunity
por: Shoji, Kensuke, et al.
Publicado: (2023)

Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States
por: D’Arcy, Monica E., et al.
Publicado: (2020)

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients
por: Pinon, Michele, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients
por: Li, Ying, et al.
Publicado: (2021)

Recurrent and metastatic squamous cell carcinoma in lung transplant recipient on voriconazole: Lessons learned
por: Zhang, Shali, et al.
Publicado: (2015)

Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients
por: Ju, Chunrong, et al.
Publicado: (2022)

Combined Effect of CYP2C19 Genetic Polymorphisms and C-Reactive Protein on Voriconazole Exposure and Dosing in Immunocompromised Children
por: Chen, Juan, et al.
Publicado: (2022)

CYP51A1 polymorphism and voriconazole-associated hepatotoxicity in children undergoing hematopoietic cell transplant
por: Takahashi, Takuto, et al.
Publicado: (2021)

Effects of voriconazole on population pharmacokinetics and optimization of the initial dose of tacrolimus in children with chronic granulomatous disease undergoing hematopoietic stem cell transplantation
por: Chen, Xiao, et al.
Publicado: (2021)

Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study
por: Suetsugu, Kimitaka, et al.
Publicado: (2021)

Population Pharmacokinetics of Caspofungin and Dose Simulations in Heart Transplant Recipients
por: Wu, Zheng, et al.
Publicado: (2022)

Pharmacokinetics and safety of two Voriconazole formulations after intravenous infusion in two doses in healthy Chinese subjects
por: Li, Xin, et al.
Publicado: (2023)

Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients
por: Liu, Xiao-Lin, et al.
Publicado: (2022)

Effective Prolonged Therapy with Voriconazole in a Lung Transplant Recipient with Spondylodiscitis Induced by Scedosporium apiospermum
por: Luijk, B., et al.
Publicado: (2011)

Topical 1% Voriconazole for Mixed Scedosporium and Exophiala Subcutaneous Infection in a Kidney Transplant Recipient
por: PACCOUD, Olivier, et al.
Publicado: (2023)

A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis
por: Kim, Yun, et al.
Publicado: (2019)

Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR Genetic Polymorphisms on Tacrolimus Metabolism in Chinese Renal Transplant Recipients
por: Li, Chuan-Jiang, et al.
Publicado: (2014)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis
por: Jiang, Zhiwen, et al.
Publicado: (2022)

Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats
por: Lee, Ji-Sang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fk4sdu1329q30ff8ogspu71ffj